The coronavirus treatment drugs market comprises pharmaceutical drugs aimed at treating COVID-19 disease caused by SARS-CoV-2 virus. Some of the major drug types currently under development include antimalarial drugs, antiviral drugs, immunomodulators, and vaccines. Antimalarial drugs like hydroxychloroquine and chloroquine are extensively studied and reported to have potential prophylactic and therapeutic effects against COVID-19. Additionally, various antiviral drugs targeting the SARS-CoV-2's protease, RNA polymerase, and spike proteins are also in clinical trials. Immunomodulators are also being researched to reduce the cytokine release syndrome in severe cases.
Key Takeaways
Key players operating in the coronavirus treatment drugs market are ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis, MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc. The widespread impact of COVID-19 pandemic has accelerated research efforts to discover effective treatment options. This presents key opportunities for industry players to develop new drugs and boost market revenues. The increasing global cases of COVID-19 are also driving collaborations between manufacturers, research organizations, and governments to fast-track clinical development of coronavirus treatment therapies. With strong government support and funding, leading drug makers are likely to expand their presence across international markets over the coming years.
Market Drivers
The growing number of Global Coronavirus Treatment Drugs Market Demand cases worldwide is one of the major drivers of coronavirus treatment drugs market. As per WHO estimates, there have been over 300 million confirmed cases globally as of January 2022, necessitating the urgent need for effective therapeutic solutions. The hospitalizations and deaths caused due to the virus have prompted governments and health agencies and ramp up research on coronavirus treatment drugs. The increasing investments by public and private players to develop novel anti-COVID drugs and vaccines are therefore expected to fuel market growth during the forecast period.
PEST Analysis
Political: The government policies and regulations related to drug testing, approval and pricing will impact the coronavirus treatment drugs market. Government support for research and clinical trials is necessary.
Economic: Global economic slowdown due to the pandemic may impact the spending capacity of customers for coronavirus treatment. However, governments are likely to prioritize healthcare spending to boost economic recovery.
Social: Rapid increase in COVID-19 cases worldwide is resulting in high demand for effective treatment options. Safety and efficacy of drugs are critical issues of public concern.
Technological: Advanced research in drug development and testing, especially for vaccines is crucial. Collaboration between academia and industry can help bring new treatment options to market faster.
Geographical concentration
In terms of revenue, North America region holds the largest share in coronavirus treatment drugs market, due to strong healthcare infrastructure and increasing investments in R&D by pharmaceutical companies. However, Asia Pacific region is expected to grow at fastest pace due to rising healthcare expenditure, large patient pool and increasing awareness about new treatment options.
Fastest growing region
Asia Pacific region is poised to grow at fastest rate for coronavirus treatment drugs market during the forecast period, mainly attributed to large population base recovering from pandemic, rising healthcare investments by governments and pharma industries, and increasing income levels of customers enabling affordability of new drug therapies. Initiatives to strengthen regional healthcare infrastructure and manufacturing capabilities also support market growth in Asia Pacific region.
Get more insights on Coronavirus Treatment Drugs Market
Comments
0 comment